SUPARTZ FX
Seikagaku Corp. · Decision date Sep 4, 2026
What did the FDA approve?
The FDA database lists decision APPR dated 2026-09-04 for supplement S067 under PMA P980044, product SUPARTZ FX. The supplement is a 135 Review Track For 30-Day Notice with reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. As stated, it approves replacing one of two existing isolators used for sterility testing of SUPARTZ FX with a new isolator equipped with an integrated hydrogen peroxide decontamination system.
The supplied fields establish the supplement-to-PMA link through the P980044 identifier; the notice covers a manufacturing change, not a new approval of the whole device. The statement gives the changed item and its decontamination method but does not describe validation data, performance of the new isolator, or any resulting effect on the product. No clinical or sterility-testing outcomes are reported, and the stated purpose is not independent evidence of safety or effectiveness. The terms of the 30-day notice review are not detailed here.
FDA approval order statement
Approval to replace one of two existing isolators used for sterility testing of SUPARTZ FX with a new isolator equipped with an integrated hydrogen peroxide decontamination system.
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Sep 4, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P980044/S067
- Regulatory pathway
- PMA supplement
- Applicant
- Seikagaku Corp.
- Product code
- MOZ
- Decision code
- APPR
- Decision date
- Sep 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Acid, hyaluronic, intraarticular.
- Applicant
- Seikagaku Corp.
- Product code
- MOZ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P980044. Subsequent supplements may change the device or its indications.
FDA decision timeline
P980044 · Original PMA
SUPARTZ FX
P980044/S063 · Related supplement
SUPARTZ FX; VISCO-3
P980044/S064 · Related supplement
SUPARTZ FX
P980044/S065 · Related supplement
SUPARTZ FX; VISCO-3
P980044/S067 received
Application receipt date recorded by FDA.
P980044/S068 · Related supplement
SUPARTZ FX
P980044/S067 · FDA decision
135 Review Track For 30-Day Notice
Timeline entries are records held by MedtechLedger for P980044. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P980044
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SUPARTZ FXP980044 | Seikagaku Corp. | PMA approval | Jan 24, 2001 | FDA |
SUPARTZ FX; VISCO-3P980044/S063 | Seikagaku Corp. | PMA supplement | Jul 22, 2025 | FDA |
SUPARTZ FXP980044/S064 | Seikagaku Corp. | PMA supplement | Aug 18, 2025 | FDA |
SUPARTZ FX; VISCO-3P980044/S065 | Seikagaku Corp. | PMA supplement | Dec 19, 2025 | FDA |
SUPARTZ FXP980044/S068 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
Explore the linked device profile
Other records with product code MOZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Gel-OneP080020/S056 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
EUFLEXXA (1% sodium hyaluronate)P010029/S043 | Ferring Pharmaceuticals, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Orthovisc Injectable Intra-Articular DevicesP030019/S028 | Anika Therapeutics, Inc. | PMA supplement | Aug 28, 2026 | FDA |
GEL-ONEP080020/S057 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
Gelsyn-3P110005/S015 | Ibsa Institut Biochimique SA | PMA supplement | Jul 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Seikagaku Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6-1, Marunouchi 1-Chome,, Chiyoda-Ku, Tokyo, 100-0005
Sources and methodology
- Original FDA record: P980044/S067
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



